Genomic Answers for Kids
A first-of-its-kind pediatric data repository to find novel treatments for pediatric genetic conditions.
GOLDILOKs® ADHD and Atomoxetine
GOLDILOKs® stands for Genomic and Ontogeny-Linked Dose Individualization and cLinical Optimization for KidS. The goal of this study is to learn how to ensure that a dose of atomoxetine is not too big, not too small, but just right for every child with attention deficit/hyperactivity disorder (ADHD).
Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma
Asthma is a very common disease in children. We know a lot about how to treat asthma. But, we still need better ways to determine which medications work best for each individual child with asthma. This study will tell us if a tool called Histamine Iontophoresis with Laser Doppler monitoring (HILDA) will be able to help us predict if adding a regularly used allergy medicine to a child’s regular asthma treatment regimen will improve their asthma symptoms.
Hypophosphatasia United States Molecular Research Center
Hypophosphatasia is a disease that affects the development of bones and teeth. Sometimes people appear to have hypophosphatasia, but their molecular testing does not reflect this diagnosis. The purpose of this research study is to take a deeper look at the genes of people who clinically appear to have the diagnosis of hypophosphatasia but do not have a pathogenic variant to prove their diagnosis.
Reaching Out for Epilepsy in Adolescents and Children through Telemedicine
Reaching Out for Epilepsy in Adolescents and Children through Telemedicine (REACT) increases access to quality, coordinated health care for children and youth with epilepsy, specifically for those residing in rural and medically underserved areas in Kansas.
Talk With Me Baby Kansas City
A program dedicated to getting families talking with their babies early.
Active clinical trials
Clinical trials are an important part of research at Children's Mercy. Each year, our researchers participate in hundreds of clinical trials.